

Clinical / Respiratory Medicine		
1	RESPIRATORY INFECTIONS IN CYSTIC FIBROSIS PATIENTS ACROSS AUSTRALIAN CAPITAL CITIES	Brittnee Bryer
2	SLEEP QUALITY AND QUANTITY: BEFORE/AFTER STARTING HIGHLY EFFECTIVE MODULATORS USING THE AWESCORE	Brenda Button
3	EFFECTIVENESS AND TOLERABILITY OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN ADULTS OVER 50 YEARS WITH CYSTIC FIBROSIS	Kim Cookson
4	FEASIBILITY, ACCEPTABILITY AND COSTS OF REMOTE MONITORING AND AUTOMATED TREATMENT PLANS: PILOT RANDOMISED CONTROLLED TRIAL	Jen Corda
5	CHARACTERISING COGNITIVE PHENOTYPES IN A PRE-CLINICAL CYSTIC FIBROSIS RAT MODEL.	Aleksandar Dobric
6	EARLY DETECTION OF REGIONAL VENTILATION ABNORMALITIES IN CHILDREN WITH CYSTIC FIBROSIS USING X-RAY VELOCIMETRY	Martin Donnelley
7	CFTR PROFILES AND PHENOTYPIC ASSOCIATIONS IN PAKISTANI CHILDREN AND ADULTS WITH SUSPECTED CYSTIC FIBROSIS	Muhammad Fareeduddin
8	MULTIDISCIPLINARY ANNUAL REVIEW IN PATIENTS WITH CYSTIC FIBROSIS; IS TELEHEALTH AN OPTION?	Jodi Grunert
9	CLINICAL OUTCOMES FOLLOWING ETI THERAPY IN SCHOOL-AGED CHILDREN WITH CF – SINGLE-CENTRE RETROSPECTIVE COHORT STUDY	A/Prof Andrew Tai
10	TOWARDS HEALTHY AGEING IN CYSTIC FIBROSIS: EARLY INSIGHTS FROM A LOCAL COHORT	Ellie Johnson
11	MANAGING VITAMIN A SUPPLEMENTATION IN ADULT CYSTIC FIBROSIS PATIENTS ON ELEXACAFTOR/TEZACAFTOR/IVACAFTOR AND ISOTRETINOIN	Ellie Johnson
12	FROM WEIGHT GAIN TO DOSE GAIN: MODERNISING TOBRAMYCIN MONITORING IN CYSTIC FIBROSIS	Ellie Johnson
13	NASAL IRRIGATION TO MONITOR AIRWAY MICROBIOLOGY IN CYSTIC FIBROSIS POST LUNG TRANSPLANT	Raynuka Lazarus
14	SAFETY, TOLERABILITY, PHARMACOKINETICS OF NOVEL NBD1 STABILIZERS SION-719 AND SION-451 FROM TWO PHASE 1 STUDIES	Cecile Le Camus
15	REBALANCING CF CARE: STRUCTURED ANNUAL REVIEW CLINICS IMPROVE OUTCOMES FOR STABLE PEOPLE WITH CF	Tracy McMahon
16	EVALUATING OPTIMAL TIMING FOR CHEST IMAGING SURVEILLANCE IN FIRST 12 MONTHS AFTER CYSTIC FIBROSIS DIAGNOSIS	Sophia Panochini
17	INCLUDING PATIENT-REPORTED OUTCOME MEASURES IN THE AUSTRALIAN CYSTIC FIBROSIS DATA REGISTRY	Claire Powell
18	EVALUATING THE ACCURACY AND QUALITY OF HOME SPIROMETRY IN AN ADULT CYSTIC FIBROSIS CENTRE	Iain Smith
19	INTRAVENOUS ANTIBIOTICS IN HOSPITAL VERSUS AT HOME - IS THERE A DIFFERENCE IN 2025?	Jan Sudario
20	PATIENTS' SATISFACTION WITH THE ANNUAL REVIEW PROCESS: A SERVICE EVALUATION STUDY	Theeba Thiruchelvam
21	THERAPEUTIC DRUG MONITORING OF CFTR MODULATORS: A SYSTEMATIC REVIEW OF BLOOD CONCENTRATION AND EXPOSURE RELATIONSHIPS	Sarah Thomas
22	LONG-TERM SAFETY AND EFFICACY OF VANZACAFTOR/TEZACAFTOR/DEUTIVACAFTOR IN CHILDREN WITH CYSTIC FIBROSIS AGED 6 YEARS AND OLDER: 96-WEEK INTERIM ANALYSIS FROM AN OPEN-LABEL EXTENSION STUDY	Claire Wainwright
23	PREGNANCY AND CFTR MODULATORS IN CYSTIC FIBROSIS: EVIDENCE ON MATERNAL SAFETY AND INFANT OUTCOMES	Zihanjiao Wang
24	PAIN IN CYSTIC FIBROSIS: PATTERNS, PROFILES AND PRACTICES FROM AN INTERNATIONAL COHORT	Anastasia Ward
25	IL-5 BIOLOGICS IN ADULT CYSTIC FIBROSIS PATIENTS WITH ASTHMA AND ABPA	Charlotte Wigston
26	ENHANCING ELEXACAFTOR/IVACAFTOR/EXPOSURE THROUGH CYP3A MEDIATED PHARMACOKINETIC BOOSTING.	Michelle Wood
27	UNDERSTANDING NON-ADOPTION AND DISCONTINUATION OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN AN ELIGIBLE CYSTIC FIBROSIS POPULATION	Michelle Wood

28	BACTERIOPHAGE ASSOCIATED LIVER INJURY IN A PERSON WITH CYSTIC FIBROSIS AND PRIOR LIVER TRANSPLANTATION	Michelle Wood
29	ION CONCENTRATIONS IN CYSTIC FIBROSIS SALIVA	Kaitlin Wyllie
30	LATE DIAGNOSIS OF CYSTIC FIBROSIS WITH CFTR POLY-T/TG TRACT VARIANTS RESPONSIVE TO ELEXACAFTOR/TEZACAFTOR/IVACAFTOR	Grace Yap
31	ULTRASLOW REINTRODUCTION OF REDUCED-DOSE ELEXACAFTOR/TEZACAFTOR/IVACAFTOR AFTER SEVERE HEPATITIS IN F508DEL HOMOZYGOUS ADULT WITH CYSTIC FIBROSIS	Grace Yap

Discovery Science

32	AZITHROMYCIN TREATMENT FOR PEDIATRIC CYSTIC FIBROSIS DOES NOT IMPACT RESPIRATORY VIROME PROFILES.	Talya Conradie
33	HOST IMMUNITY AND CLINICAL RESPONSE HETEROGENEITY IN CF PATIENTS	Ama-Tawiah Essilfie
34	STAKEHOLDER ACCEPTABILITY OF PATIENT-DERIVED ORGANOID FOR PERSONALISED MEDICINE IN CYSTIC FIBROSIS	Laura Fawcett
35	MODULATING MORE THAN CF: A PROTEOMIC PROBE INTO DRUG-INDUCED LIVER INJURY	Daniel Smith
36	SMALL MOLECULE NBD1 STABILIZERS CAN INCREASE THE HALF-LIFE OF F508DEL-CFTR TO THAT OF WILD-TYPE CFTR	Cecile Le Camus
37	ANTIBODY-MEDIATED INHIBITION OF PHAGE KILLING AGAINST PSEUDOMONAS AERUGINOSA	Emma Ledger
38	AZITHROMYCIN MODULATES RHINOVIRUS-DRIVEN INFLAMMATORY SIGNALLING IN CYSTIC FIBROSIS BRONCHIAL EPITHELIAL CELLS	Kak Ming Ling
39	BACTERIOPHAGE MANUFACTURING FOR HUMAN THERAPEUTICS: A SCALABLE APPROACH	Kak Ming Ling
40	ENHANCING CYSTIC FIBROSIS LUNG GENE THERAPY USING HYPERTONIC SALINE AIRWAY CONDITIONING	Alexandra McCarron
41	A PRACTICAL LC-MS/MS APPROACH FOR QUANTIFYING FREE AND TOTAL CFTR MODULATOR CONCENTRATIONS	Sarah Thomas

Endocrinology

42	ANDROGEN MISUSE IN MEN WITH CYSTIC FIBROSIS	Shanal Kumar
43	HIGH PREVALENCE OF OSTEOPAENIA AND OSTEOPOROSIS USING DUAL XRAY ABSORPTIOMETRY SCREENING	Shanal Kumar
44	PREVALENCE AND PREDICTORS OF FRACTURE IN ADULTS WITH CYSTIC FIBROSIS: A SINGLE AUSTRALIAN CENTRE AUDIT	Angela Matson
45	GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE IS ASSOCIATED WITH IMPROVED LUNG FUNCTION IN CYSTIC FIBROSIS	Judith Morton
46	DIABETES EDUCATION AND TECHNOLOGIES IMPROVE GLYCAEMIC OUTCOME IN CYSTIC-FIBROSIS-RELATED-DIABETES: A CASE REPORT	Soon Yi Tan

GI / Nutrition

46	DIABETES EDUCATION AND TECHNOLOGIES IMPROVE GLYCAEMIC OUTCOME IN CYSTIC-FIBROSIS-RELATED-DIABETES: A CASE REPORT	Soon Yi Tan
47	DOES DELIVERY MEDIUM MATTER? GROWTH OUTCOMES WITH DIFFERENT PERT ADMINISTRATION METHODS IN INFANTS WITH CF	Martha Churchett
48	PROTON PUMP INHIBITOR EXPOSURE AND EARLY GUT MICROBIOME DEVELOPMENT IN YOUNG CHILDREN WITH CYSTIC FIBROSIS	Michael Coffey
49	COMPARING DIETARY ASSESSMENT METHODS IN ADULTS WITH CYSTIC FIBROSIS: IMPLICATIONS FOR MONITORING DIET QUALITY.	Cian Greaney
50	ELEXACAFTOR/TEZACAFTOR/IVACAFTOR DOSE ADJUSTMENT FOR WEIGHT GAIN IN PEDIATRIC CF PATIENTS	Jodi Grunert
51	EFFECTS OF TRIKAFTA ON RESTING ENERGY EXPENDITURE (REE) IN CHILDREN WITH CYSTIC FIBROSIS (CF)	Carla Hall

52	BODY COMPOSITION CHANGES IN CHILDREN WITH CYSTIC FIBROSIS COMMENCING TRIKAFTA	Carla Hall
53	AUDIT OF DIETETIC HANDOVER FOR PEOPLE WITH CYSTIC FIBROSIS TRANSITIONING FROM PAEDIATRIC TO ADULT CENTRE	Jordan Henderson
54	SHOULD WE BE WORRIED ABOUT NORMAL WEIGHT OBESITY IN PEOPLE WITH CYSTIC FIBROSIS?	Shanal Kumar
55	ROUTINE SCREENING FOR DISORDERED EATING IN AN ADULT CYSTIC FIBROSIS CENTRE	Felicity Loel
56	COLORECTAL CANCER SCREENING IN ADULT CF CARE: ARE WE MEETING THE MARK?	Angela Matson
57	EFFECTIVENESS OF CFTR MODULATOR THERAPY ON GASTROINTESTINAL CLEARANCE IN PEOPLE WITH CYSTIC FIBROSIS REQUIRING COLONOSCOPY.	Angela Matson
58	THE PaNC STUDY: 12 MONTH INTERIM RESULTS	Caitlin Miles
59	GASTROINTESTINAL SYMPTOMS IN PEOPLE WITH CYSTIC FIBROSIS SEEN IN AN OUTPATIENT CLINIC	Erin O'Neill
60	A CASE OF SEMAGLUTIDE-ASSOCIATED SMALL BOWEL OBSTRUCTION IN CYSTIC FIBROSIS	Koliarne Tong

Physiotherapy

61	HOSPITALISATION AND PHYSIOTHERAPY MANAGEMENT OF ADULTS WITH CYSTIC FIBROSIS IN THE POST MODULATOR ERA	Robyn Cobb
62	RE-SHAPING PROFESSIONAL DEVELOPMENT FOR THE FUTURE OF CYSTIC FIBROSIS PHYSIOTHERAPY MANAGEMENT.	Jenny Hauser
63	PHYSIOTHERAPY FOR CYSTIC FIBROSIS EXACERBATIONS: A SYSTEMATIC REVIEW OF CLINICAL PRACTICE GUIDELINES	Nathan Ward
64	PHYSIOTHERAPY ANNUAL REVIEWS IN CYSTIC FIBROSIS: WHAT IS REALLY HAPPENING?	Jennifer Bishop

Psychosocial / Nursing / Education

65	CO-DESIGNING AND PILOTING THE PARTNERSHIP ENHANCEMENT PROGRAM (PEP) FOR AUSTRALIA	Judith Glazner
66	CONSUMER PERSPECTIVES OF WELLBEING SUPPORT IN PEDIATRIC CYSTIC FIBROSIS CARE	Caitlyn Gourlay
67	FINANCIAL BURDEN OF CYSTIC FIBROSIS IN AUSTRALIA: FINDINGS FROM A NATIONAL SURVEY	Genevieve Handley
68	EMBRACING TOMORROW: COLLABORATION FOR IMPACT IN THE MODERN CYSTIC FIBROSIS ERA	Jes Jackson
69	MENTAL HEALTH SCREENING IN NEW SOUTH WALES ADOLESCENTS WITH CYSTIC FIBROSIS	Stella Li
70	SPONTANEOUS GASTROSTOMY CLOSURE FAILURE IN CYSTIC FIBROSIS: INSIGHTS FROM A CASE SERIES	Tracy McMahon
71	ESTABLISHING AND SUSTAINING A NATIONAL CYSTIC FIBROSIS SOCIAL WORK PEER SUPPORT NETWORK AROUND AUSTRALIA.	Rebecca Norden
72	RELATIONSHIP BETWEEN SLEEP, FAMILY DYNAMICS AND MENTAL HEALTH IN ADOLESCENTS LIVING WITH CYSTIC FIBROSIS	Hiep Pham
73	EVALUATING QUALITY OF LIFE IMPROVEMENTS IN CHILDREN WITH CYSTIC FIBROSIS FOLLOWING ELEXACTOR, TEZACAFOR/ IVACFTOR TREATMENT.	Sarah-jane Sheedy
74	IMPLEMENTATION AND EVALUATION OF A CYSTIC FIBROSIS (CF) CLINICAL NURSE CONSULTANT (CNC) MODEL OF CARE	Elena Sunderland